INBS Valuation
Intelligent Bio Solutions Inc
$
1.470
- Overview
- Forecast
- Valuation
- Earnings
INBS Relative Valuation
INBS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, INBS is overvalued; if below, it's undervalued.
Historical Valuation
Intelligent Bio Solutions Inc (INBS) is now in the Fair zone, suggesting that its current forward PS ratio of 0.88 is considered Fairly compared with the five-year average of -1.86. The fair price of Intelligent Bio Solutions Inc (INBS) is between 0.92 to 1.52 according to relative valuation methord.
Relative Value
Fair Zone
0.92-1.52
Current Price：1.47
Fair
-1.18
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
Intelligent Bio Solutions Inc. (INBS) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.
-1.37
EV/EBIT
Intelligent Bio Solutions Inc. (INBS) has a current EV/EBIT of -1.37. The 5-year average EV/EBIT is -0.60. The thresholds are as follows: Strongly Undervalued below -2.38, Undervalued between -2.38 and -1.49, Fairly Valued between 0.29 and -1.49, Overvalued between 0.29 and 1.18, and Strongly Overvalued above 1.18. The current Forward EV/EBIT of -1.37 falls within the Historic Trend Line -Fairly Valued range.
0.88
PS
Intelligent Bio Solutions Inc. (INBS) has a current PS of 0.88. The 5-year average PS is 16.09. The thresholds are as follows: Strongly Undervalued below -54.62, Undervalued between -54.62 and -19.26, Fairly Valued between 51.45 and -19.26, Overvalued between 51.45 and 86.81, and Strongly Overvalued above 86.81. The current Forward PS of 0.88 falls within the Historic Trend Line -Fairly Valued range.
-9.30
P/OCF
Intelligent Bio Solutions Inc. (INBS) has a current P/OCF of -9.30. The 5-year average P/OCF is -2.51. The thresholds are as follows: Strongly Undervalued below -9.00, Undervalued between -9.00 and -5.76, Fairly Valued between 0.73 and -5.76, Overvalued between 0.73 and 3.98, and Strongly Overvalued above 3.98. The current Forward P/OCF of -9.30 falls within the Strongly Undervalued range.
0.00
P/FCF
Intelligent Bio Solutions Inc. (INBS) has a current P/FCF of 0.00. The 5-year average P/FCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/FCF of 0.00 falls within the Strongly Undervalued range.
Intelligent Bio Solutions Inc (INBS) has a current Price-to-Book (P/B) ratio of 1.95. Compared to its 3-year average P/B ratio of 1.15 , the current P/B ratio is approximately 70.04% higher. Relative to its 5-year average P/B ratio of 1.56, the current P/B ratio is about 25.21% higher. Intelligent Bio Solutions Inc (INBS) has a Forward Free Cash Flow (FCF) yield of approximately -103.67%. Compared to its 3-year average FCF yield of -158.37%, the current FCF yield is approximately -34.54% lower. Relative to its 5-year average FCF yield of -113.13% , the current FCF yield is about -8.37% lower.
1.95
P/B
Median3y
1.15
Median5y
1.56
-103.67
FCF Yield
Median3y
-158.37
Median5y
-113.13
Competitors Valuation Multiple
The average P/S ratio for INBS's competitors is 0.60, providing a benchmark for relative valuation. Intelligent Bio Solutions Inc Corp (INBS) exhibits a P/S ratio of 0.88, which is 46.83% above the industry average. Given its robust revenue growth of -11.52%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of INBS increased by 4.26% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -0.51 to -0.61.
The secondary factor is the Margin Expansion, contributed -3.48%to the performance.
Overall, the performance of INBS in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
DSS
DSS Inc
0.835
USD
+0.36%
DDC
DDC Enterprise Ltd
10.250
USD
+1.49%
CERO
CERo Therapeutics Holdings Inc
8.000
USD
-1.36%
SSY
SunLink Health Systems Inc
0
USD
+13.90%
GBR
New Concept Energy Inc
0.995
USD
+16.51%
WHLR
Wheeler Real Estate Investment Trust Inc
2.040
USD
-3.32%
BON
Bon Natural Life Ltd
1.300
USD
0.00%
BTOG
Bit Origin Ltd
0.511
USD
0.00%
FAQ
Is Intelligent Bio Solutions Inc (INBS) currently overvalued or undervalued?
Intelligent Bio Solutions Inc (INBS) is now in the Fair zone, suggesting that its current forward PS ratio of 0.88 is considered Fairly compared with the five-year average of -1.86. The fair price of Intelligent Bio Solutions Inc (INBS) is between 0.92 to 1.52 according to relative valuation methord.
What is Intelligent Bio Solutions Inc (INBS) fair value?
How does INBS's valuation metrics compare to the industry average?
What is the current P/B ratio for Intelligent Bio Solutions Inc (INBS) as of Aug 18 2025?
What is the current FCF Yield for Intelligent Bio Solutions Inc (INBS) as of Aug 18 2025?
What is the current Forward P/E ratio for Intelligent Bio Solutions Inc (INBS) as of Aug 18 2025?